Active substance
Hyoscine
- US FDA 8
- Health Canada 2
- US price lines 1
- NHS prices 4
- WHO EML 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TRANSDERM SCOP | 1MG/72HR | system · transdermal | BAXTER HLTHCARE CORP | Prescription | 31 Dec 1979 |
| SCOPOLAMINE | 1MG/72HR | system · transdermal | PADAGIS US | Prescription | 30 Jan 2015 |
| SCOPOLAMINE | 1MG/72HR | system · transdermal | MYLAN TECHNOLOGIES | Prescription | 19 Jun 2019 |
| SCOPOLAMINE | 1MG/72HR | system · transdermal | RICONPHARMA LLC | Prescription | 24 Nov 2020 |
| SCOPOLAMINE | 1MG/72HR | system · transdermal | ACTAVIS LABS UT INC | Prescription | 10 Jan 2022 |
| SCOPOLAMINE | 1MG/72HR | system · transdermal | RHODES PHARMS | Prescription | 6 May 2024 |
| SCOPOLAMINE | 1MG/72HR | system · transdermal | ZYDUS PHARMS | Prescription | 29 Aug 2024 |
| SCOPOLAMINE | 1MG/72HR | system · transdermal | AMNEAL | Prescription | 9 Jun 2025 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| SCOPOLAMINE HYDROBROMIDE INJECTION | 02242810 | 0.4 MG / ML | LIQUID · INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS | JUNO PHARMA CANADA INC. |
| SCOPOLAMINE HYDROBROMIDE INJECTION | 02242811 | 0.6 MG / ML | LIQUID · INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS | JUNO PHARMA CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SCOPOLAMINE 1 MG/3 DAY PATCH | $4.33565 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Hyoscine hydrobromide 150microgram tablets | £2.50 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Hyoscine hydrobromide 300microgram tablets | £2.50 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Hyoscine hydrobromide 400micrograms/1ml solution for injection ampoules | £22.70 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Hyoscine hydrobromide 600micrograms/1ml solution for injection ampoules | £224.13 | 10 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 2.3. Medicines for other common symptoms in palliative care · core
Palliative care
Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch (EMLc) | Parenteral > General injections > unspecified: 400 µg per mL injection (EMLc); 600 µg per mL injection (EMLc)
Safety signals and safety-related labeling changes
- US FDA 25 Apr 2025 TRANSDERM SCOP — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.